We synthesized various pyrazine derivatives and pyrazinamide analogs and assayed their antimycobacterial activities in vitro in order to find new drugs which are more active against Mycobacterium tuberculosis than pyrazinamide and also active against Mycobacterium avium and Mycobacterium intracellulare. Of the drugs synthesized, four drugs, namely, pyrazine thiocarboxamide, N-hydroxymethyl pyrazine thiocarboxamide, pyrazinoic acid n-octyl ester, and pyrazinoic acid pivaloyloxymethyl ester, were not only bacteriostatic but also bacteriocidal against these three species of mycobacteria in vitro under conditions in which pyrazinamide showed no or little activity. In conclusion, these four drugs are possible candidates for new antimycobacterial agents, and animal experiments are now under way.
Pyrazinamide is one of the most effective antituberculosis drugs and is believed to be particularly effective against tubercle bacilli within host phagocytes and/or in acidic environments (12, 15) . However, pyrazinamide has some drawbacks: it is associated with a rather high incidence of liver dysfunction and hyperuricemia, it is ineffective against Mycobacterium avium complex (MAC), and it is difficult to use in susceptibility tests in ordinary clinical laboratories (19) . Tuberculosis still remains a major cause of death in many developing countries and also is resurging in developed countries as nosocomial outbreaks caused by multidrug-resistant tubercle bacilli (18) . Furthermore, MAC infections, especially disseminated ones, are now one of the most serious complications in patients with AIDS (2, 9) . Consequently, it is urgently necessary to develop antimycobacterial drugs which are more effective than pyrazinamide against Mycobacterium tuberculosis and also effective against MAC. Attempting to find such drugs among pyrazine derivatives or pyrazinamide analogs, we synthesized 39 derivatives and assayed their antimycobacterial activities in vitro. Four of these new compounds exhibited strong antimycobacterial activities.
MATERIALS AND METHODS (i) Test drugs.
Pyrazinamide was obtained commercially from Sankyo Pharmaceutical Co. (Tokyo, Japan). Pyrazinoic acid and other starting materials for synthesis were of reagent grade and were obtained from Wako Pure Chemicals Ind., Ltd. (Osaka, Japan).
The methods of synthesis and chemical structures of the four compounds that exhibited high levels of antimycobacterial activities are described below. The chemical structures of these compounds were determined by their mass and nuclear magnetic resonance (NMR) spectra, which were recorded with an R-1100 spectrometer (Hitachi Ltd., Ibaragi, Japan) and with a QP-1000EX spectrometer (Shimadzu Corp., Kyoto, Japan), respectively.
(a) Pyrazinoic acid pivaloyloxymethyl ester. The sodium salt of pyrazinoic acid (14.6 g, 0.10 mol) was reacted with pivaloyloxymethyl chloride (15.1 g, 0.10 mol) in N,N-dimethylformamide (16.0 g) at 100 to 110ЊC for 8 h. The resultant mixture was filtered and distilled under reduced pressure to give the title compound, with the following characteristics: mp, 25 to 32ЊC; bp, 135 to 137ЊC/470 Pa; 1 
tuberculosis, M. avium, and
Mycobacterium intracellulare were used. Clinical strains were isolated from sputa of patients with pulmonary mycobacterial diseases and identified by the RNA-DNA hybridization method (Accu Probe; Gene Probe Inc., San Diego, Calif.). These strains were kept frozen and were thawed, cultured in Middlebrook 7H9 broth, and subcultured in the same medium. The second subcultures were used at the exponential growth phase for the experiments after the turbidity at 530 nm (optical density [OD]) was adjusted to 0.132 (inoculum culture).
(iii) Screening test. Each drug, including pyrazinamide, was dissolved in dimethyl sulfoxide and added to Middlebrook 7H9 broth (adjusted to pH 6.0) to obtain a final concentration of 200 g/ml. One-tenth of a milliliter of the abovementioned inoculum culture was added to 5.0 ml of drug-containing and drugfree control 7H9 broth (in culture tubes [14.5 by 1.8 cm]) and cultured at 37ЊC. The OD was read on every second or third day after gentle shaking at 530 nm with a photoelectric photometer (model EPO-B; Hirayama Sangyo Co., Ltd., Tokyo, Japan). The OD of the drug-containing culture was compared with that of the pyrazinamide-containing culture on day 7 for M. intracellulare, on day 14 for M. avium, and on day 21 for M. tuberculosis, when the OD of the drug-free control culture of the respective mycobacterial species reached approximately 0.400.
(iv) Bacteriostatic activity. One-tenth of a milliliter of the inoculum culture was inoculated into 5.0 ml of Middlebrook 7H9 broth, pH 6.0, with or without a drug. The OD of drug-containing culture was compared with that of the control culture without a drug on day 7 for M. intracellulare, on day 14 for M. avium, and on day 21 for M. tuberculosis. The growth inhibition rate (GIR) was calculated from the ratio of OD of the drug-containing culture (OD-TD) to that of the culture without a drug (OD-Cont) as (1 Ϫ OD-TD/OD-Cont) ϫ 100.
(v) Bacteriocidal activity. Predetermined numbers (0.94 ϫ 10 6 to 1.4 ϫ 10 6 in the case of MAC and 2.2 ϫ 10 5 to 7.4 ϫ 10 5 in the case of M. tuberculosis) of mycobacteria were inoculated into 5.0 ml of Middlebrook 7H9 broth, pH 6.0, in the presence of a drug. After cultivation for 7 days for M. intracellulare, for 14 days for M. avium, or for 21 days for M. tuberculosis, the culture was serially diluted and inoculated onto Ogawa egg medium and cultured at 37ЊC for 4 weeks to determine the number of remaining live mycobacteria. The killing rate (KR) was calculated from the ratio of the number of live mycobacteria after the cultivation in the presence of a drug (CFU-TD) to the number of the mycobacteria inoculated initially (CFU-Init) as (1 Ϫ CFU-TD/CFU-Init) ϫ 100.
RESULTS
(i) Effect of pH on antimycobacterial activity of the drug. As is well known, pyrazinamide is more effective in acidic media than in a neutral one (15) , but the growth of mycobacteria is rather poor and inconsistent in acidic media. To determine which pH is appropriate for a screening medium, we compared the antimycobacterial activities of pyrazinamide in Middlebrook 7H9 broth adjusted to pH 6.0 and to pH 5.5.
As shown in Fig. 1 , the growth of M. intracellulare in medium with a pH of 5.5 was much poorer than in medium with a pH of 6.0. Essentially the same results were observed with other analogs and with M. avium and M. tuberculosis (data were not shown).
From these results, we decided to use Middlebrook 7H9 broth adjusted to pH 6.0 for further experiments.
(ii) Screening test. Drugs were ranked as A, B, or C if the OD ratio [(OD-TD/OD-PZA) ϫ 100] was equal to or less than 10%, 11 to 20%, or 21 to 30%, respectively. Among the 39 compounds tested, pyrazinoic acid pivaloyloxymethyl ester, pyrazinoic acid n-octyl ester, pyrazine thiocarboxamide, and N-hydroxymethyl pyrazine thiocarboxamide were ranked as A with M. tuberculosis and M. intracellulare. With M. avium, Nhydroxymethyl pyrazine thiocarboxamide and pyrazinoic acid pivaloyloxymethyl ester were ranked as A, too, and pyrazinoic acid n-octyl ester was ranked as B and pyrazine thiocarboxam- ide was ranked as C. Thus, these four drugs were selected for further examinations.
(iii) Growth-inhibitory and bacteriocidal activities of the drugs. The GIR and KR of these four drugs for an American Type Culture Collection strain as well as a couple of clinical isolates of each three mycobacterial species were determined. The results are shown in Tables 1 to 3. For M. intracellulare, all four drugs at concentrations of 200 g/ml were bacteriostatic as well as bacteriocidal against all four strains tested.
For M. avium, pyrazinoic acid n-octyl ester and N-hydroxymethyl pyrazine thiocarboxamide at 200 g/ml were bacteriostatic and also bacteriocidal against all four strains tested, and pyrazinoic acid pivaloyloxymethyl ester and pyrazine thiocarboxamide at 200 g/ml were bacteriocidal against one or two strains tested.
For M. tuberculosis, all four drugs at 100 g/ml were bacteriostatic and bacteriocidal against all three strains tested.
Under the experimental conditions, pyrazinamide at 200 g/ml was neither bacteriostatic nor bacteriocidal against any strain of MAC and was slightly bacteriostatic but not bacteriocidal against M. tuberculosis.
(iv) Minimal effective concentrations of the drugs. The MICs and MBCs of the four drugs were determined. The a M. tuberculosis was exposed for 3 weeks to a 100-g/ml concentration of each drug. results are summarized in Table 4 . Under the experimental conditions, pyrazinamide at 200 g/ml was not bacteriocidal against any of the mycobacterial species tested. Pyrazinoic acid pivaloyloxymethyl ester at 100 g/ml was highly bacteriocidal against M. intracellulare and at 50 g/ml was highly bacteriocidal against M. avium and M. tuberculosis. Pyrazinoic acid n-octyl ester at 200 g/ml was highly bacteriocidal against M. intracellulare and M. avium and at 100 g/ml was highly bacteriocidal against M. tuberculosis. Pyrazine thiocarboxamide at 200 g/ml was highly bacteriocidal against M. avium and at 100 g/ml was highly bacteriocidal against M. intracellulare and M. tuberculosis. N-Hydroxymethyl pyrazine thiocarboxamide at 100, 50, and 25 g/ml was highly bacteriocidal against M. intracellulare, M. avium, and M. tuberculosis, respectively. In most cases, significant growth inhibition was observed at a twofold-lower concentration than needed for complete killing.
DISCUSSION
Pyrazinamide was first synthesized by Hall and Spoerri (6) as an intermediate compound on the pathway of aminopyrazine synthesis, but its antimycobacterial activity was reported later, in 1952 (3, 4, 13, 20) . In the same year, Kushner et al. (11) reported the synthesis of 49 pyrazinamide derivatives and 14 related compounds and briefly referred to their antimycobacterial activities in an in vivo murine system without supplying any information on their in vitro antimycobacterial activities.
Pyrazinamide is a unique antituberculosis drug. It shows rather weak activity in neutral medium but is moderately active in acidic medium in vitro (15) and is effective against tubercle bacilli within phagocytes (12) . Furthermore, it is highly effective against murine experimental tuberculosis in combination with isoniazid (14) and is the third most important drug behind isoniazid and rifampin in short-course chemotherapy for human tuberculosis (1, 5, 19) .
The mode of action of pyrazinamide has not been conclusively established, but it is postulated that pyrazinamide exerts its antimycobacterial activity after conversion to the active agent, pyrazinoic acid, within bacterial cells by a bacterial enzyme, pyrazinamide deamidase (8, 10, 16) . If this hypothesis is valid, it may be possible to find new drugs with a similar mode of action among pyrazinamide analogs, despite the negative reports by Kushner et al. (11) . With such an assumption, we synthesized various analogs of pyrazinamide and examined their antimycobacterial activities in vitro.
In these experiments, four compounds showed high levels of antimycobacterial activities, not only bacteriostatic but also bacteriocidal, against M. tuberculosis as well as MAC. These compounds, namely, pyrazinoic acid pivaloyloxymethyl ester, pyrazinoic acid n-octyl ester, pyrazine thiocarboxamide, and N-hydroxymethyl pyrazine thiocarboxamide, may warrant further examinations.
Throughout these studies, Middlebrook 7H9 broth adjusted to pH 6.0 was used. As is well known, pyrazinamide is more active in a more acidic environment, such as pH 5.0, than at pH 6.0 (15, 17) . However, at such a low pH, the growth of mycobacteria is very poor and inconsistent. Furthermore, the relative antimycobacterial activities of the drugs compared with that of pyrazinamide were essentially the same in medium with a pH of 6.0 as in medium with a pH of 5.5. Other authors also used medium with a pH of 6.0 for testing of susceptibility to pyrazinamide for the same reasons (7, 16, 17) .
The effectiveness of the candidate drugs against experimental tuberculosis in mice is now being studied.
